Septerna Inc.

6.26
0.19 (3.13%)
At close: Apr 15, 2025, 3:59 PM
6.14
-2.00%
After-hours: Apr 15, 2025, 04:42 PM EDT
3.13%
Bid 5.95
Market Cap 278.43M
Revenue (ttm) 539K
Net Income (ttm) -17.24M
EPS (ttm) -7.26
PE Ratio (ttm) -0.86
Forward PE n/a
Analyst Buy
Ask 6.48
Volume 139,728
Avg. Volume (20D) 525,959
Open 6.07
Previous Close 6.07
Day's Range 5.99 - 6.30
52-Week Range 4.17 - 28.99
Beta 4.26

About SEPN

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Prog...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2024
Employees 75
Stock Exchange NASDAQ
Ticker Symbol SEPN
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for SEPN stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 506.54% from the latest price.

Stock Forecasts
1 month ago
-46.99%
Septerna shares are trading lower after the compan... Unlock content with Pro Subscription